Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic bone marrow mesenchymal stromal cells for COVID-19-related acute respiratory distress syndrome
2020-002193-27Phase 2Active
- Sponsor
- Cristina Avendano-Sola
- Start
- Jul 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL) in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Cristina Avendano-Sola. Primary endpoint: Change in PaO2/FiO2 ratio. Started Jul 2020; status: active.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL)
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2020-002193-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002193-27.